Severe IgE-mediated Asthma
1 clinical trials · Condition
◉ Watch Severe IgE-mediated Asthma
| Record | Firm | Date |
|---|---|---|
| Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma (NCT01912872) | Novartis Pharmaceuticals | 2013-11-11 |
Track Severe IgE-mediated Asthma automatically
Every clearance here is in the API, with alerts when new ones post.